H World Group Posts Upbeat Q3 Earnings, Joins CG Oncology, TELUS And Other Big Stocks Moving Higher On Monday
U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.
Stocks · News reference
Filed: 2026-11-05 AccNo: 0001193125-26-449985 Size: 13 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
U.S. stocks fell, but H World Group surged 9.3% on strong Q3 results and raised guidance; several other stocks posted notable gains.
Analyst Matthew Keller of H.C. Wainwright maintained a "Buy" rating and $18 price target on Gyre Therapeutics.
Gyre Therapeutics reported its third quarter 2026 financial results, including $32.9 million in revenue, and affirmed its full-year 2026 revenue guidance.
Gyre Therapeutics, Inc. has entered into an employment agreement with Thomas Eastling to serve as the company's Chief Financial Officer.
Gyre Therapeutics, Inc. has entered into an employment agreement with Ying Luo to serve as the company's Chief Executive Officer.